Evofem Narrows Losses Amidst Sales Dip, Going Concern Looms

TL;DR

**Evofem is still bleeding cash and facing a going concern, making it a high-risk bet despite narrowing losses.**

AI Summary

Evofem Biosciences, Inc. reported a net loss of $828,000 for the six months ended June 30, 2025, a significant improvement from the $3.458 million net loss in the same period of 2024. Product sales, net, decreased to $5.670 million for the six months ended June 30, 2025, compared to $7.763 million in 2024. However, for the three months ended June 30, 2025, product sales increased to $4.825 million from $4.160 million in the prior year. The company's total assets declined to $14.382 million as of June 30, 2025, from $23.789 million at December 31, 2024, while total liabilities also decreased to $79.212 million from $90.264 million. A notable change was the $5.607 million gain on accounts payable and accrued expenses settlements, contributing to a reduced net cash used in operating activities of $2.359 million for the six months ended June 30, 2025, compared to $1.018 million in 2024. The company continues to face a going concern risk and has identified material weaknesses in internal controls.

Why It Matters

Evofem's ability to reduce its net loss to $828,000 for the first half of 2025, despite a decline in product sales, suggests some operational efficiency gains, but the persistent 'going concern' warning is a red flag for investors. The competitive landscape for women's reproductive health products, particularly non-hormonal contraceptives like PHEXXI, is intense, with larger pharmaceutical companies often having greater marketing and distribution reach. Employees face uncertainty given the company's financial instability and the need to raise additional capital. Customers relying on PHEXXI could see potential disruptions if the company's financial challenges escalate, impacting product availability or support. The broader market will watch if Evofem can successfully navigate its debt obligations and secure necessary funding to remain a viable player in this niche.

Risk Assessment

Risk Level: high — The company explicitly states its 'ability to continue as a going concern' is a significant risk. Total liabilities of $79.212 million far exceed total assets of $14.382 million as of June 30, 2025, indicating severe financial distress. Furthermore, the company reported a net cash used in operating activities of $2.359 million for the six months ended June 30, 2025, demonstrating continued cash burn.

Analyst Insight

Investors should exercise extreme caution and avoid EVFM due to the explicit 'going concern' warning, substantial liabilities, and ongoing cash burn. Potential investors should wait for clear evidence of sustained profitability and a strengthened balance sheet before considering any position.

Financial Highlights

debt To Equity

N/A

revenue

$5.67M

operating Margin

N/A

total Assets

$14.382M

total Debt

N/A

net Income

-$828K

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

-26.9%

Revenue Breakdown

Key Numbers

• $828K — Net Loss (for six months ended June 30, 2025, improved from $3.458M in 2024)
• $5.67M — Product Sales, Net (for six months ended June 30, 2025, decreased from $7.763M in 2024)
• $4.825M — Product Sales, Net (for three months ended June 30, 2025, increased from $4.160M in 2024)
• $14.382M — Total Assets (as of June 30, 2025, down from $23.789M at Dec 31, 2024)
• $79.212M — Total Liabilities (as of June 30, 2025, down from $90.264M at Dec 31, 2024)
• $2.359M — Net Cash Used in Operating Activities (for six months ended June 30, 2025, increased from $1.018M in 2024)
• $5.607M — Gain on Accounts Payable Settlements (contributed to reduced net loss)
• 118,656,354 — Common Shares Outstanding (as of August 9, 2025)

Key Players & Entities

• Evofem Biosciences, Inc. (company) — registrant
• FDA (regulator) — approved PHEXXI
• PHEXXI (company) — commercial product
• SOLOSEC (company) — commercial product
• Future Pak, LLC (company) — received Notice of Default
• Aditxt (company) — related party for notes
• $828,000 (dollar_amount) — net loss for six months ended June 30, 2025
• $3.458 million (dollar_amount) — net loss for six months ended June 30, 2024
• $5.670 million (dollar_amount) — product sales for six months ended June 30, 2025
• $14.382 million (dollar_amount) — total assets as of June 30, 2025

FAQ

Risk Factors

• Going Concern Risk [high — financial]: The company continues to face substantial doubt about its ability to continue as a going concern. This is primarily due to its recurring losses and negative cash flows from operations, despite recent improvements.
• Material Weaknesses in Internal Controls [high — operational]: Evofem has identified material weaknesses in its internal control over financial reporting. These weaknesses could result in a misstatement of its financial statements that is not prevented or detected in a timely manner.
• Significant Decline in Assets [medium — financial]: Total assets have decreased significantly to $14.382 million as of June 30, 2025, from $23.789 million at December 31, 2024. This reduction may impact the company's operational capacity and future growth prospects.
• High Liabilities Relative to Assets [high — financial]: Despite a decrease in total liabilities to $79.212 million from $90.264 million, liabilities still substantially exceed total assets, indicating a precarious financial position.

Industry Context

Evofem Biosciences operates in the women's health sector, specifically focusing on contraceptive products. The market is competitive, with established players and ongoing innovation. Trends include a growing demand for non-hormonal and user-controlled options, but market access, physician adoption, and reimbursement remain key challenges.

Regulatory Implications

As a pharmaceutical company, Evofem is subject to stringent regulatory oversight by bodies like the FDA. Compliance with manufacturing standards, marketing regulations, and post-market surveillance is critical. Any adverse regulatory actions could significantly impact product sales and the company's financial health.

What Investors Should Do

1. Monitor quarterly sales trends closely.
2. Evaluate the company's ability to address going concern risk.
3. Assess the impact of material weaknesses in internal controls.
4. Analyze the sustainability of the improved net loss.

Key Dates

• 2025-06-30: Six Months Ended — Reported a net loss of $828,000, an improvement from $3.458 million in the prior year. Product sales were $5.670 million, down from $7.763 million.
• 2025-06-30: Three Months Ended — Product sales increased to $4.825 million from $4.160 million in the prior year, showing a recent positive sales trend.
• 2025-06-30: Balance Sheet Date — Total assets stood at $14.382 million, and total liabilities were $79.212 million.
• 2024-12-31: Prior Year End Balance Sheet — Total assets were $23.789 million, and total liabilities were $90.264 million.

Glossary

Going Concern

An assumption that a company will continue to operate for the foreseeable future. If there is substantial doubt about this, it must be disclosed. (Evofem faces substantial doubt about its ability to continue as a going concern, a critical risk for investors.)

Material Weakness

A deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim financial statements will not be prevented or detected on a timely basis. (The presence of material weaknesses raises concerns about the reliability of Evofem's financial reporting.)

Net Cash Used in Operating Activities

The net amount of cash used by a company's core business operations during a period. A negative number indicates cash outflow. (While reduced to $2.359 million for the six months ended June 30, 2025, this still represents a significant cash burn from operations.)

Gain on Accounts Payable and Accrued Expenses Settlements

A non-operating gain recognized when a company settles its outstanding payables and accrued expenses for less than their carrying amount. (This $5.607 million gain significantly improved the net loss but is a one-time event and not indicative of ongoing operational performance.)

Year-Over-Year Comparison

Compared to the prior year's six-month period, Evofem Biosciences reported a significantly reduced net loss of $828,000 versus $3.458 million, largely due to a substantial gain on accounts payable settlements. However, net product sales for the six months declined by 26.9% to $5.67 million from $7.763 million, indicating a challenging sales environment. Total assets and liabilities have both decreased, reflecting a deleveraging effort, but the company's financial position remains weak with significant liabilities exceeding assets.

Filing Documents

• form10-q.htm (10-Q) — 1872KB
• ex31-1.htm (EX-31.1) — 19KB
• ex31-2.htm (EX-31.2) — 18KB
• ex32-1.htm (EX-32.1) — 12KB
• 0001641172-25-023741.txt ( ) — 10051KB
• evfm-20250630.xsd (EX-101.SCH) — 59KB
• evfm-20250630_cal.xml (EX-101.CAL) — 71KB
• evfm-20250630_def.xml (EX-101.DEF) — 283KB
• evfm-20250630_lab.xml (EX-101.LAB) — 511KB
• evfm-20250630_pre.xml (EX-101.PRE) — 416KB
• form10-q_htm.xml (XML) — 2126KB

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS 1 PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Operations 5 Condensed Consolidated Statements of Convertible and Redeemable Preferred Stock and Stockholders' Deficit 6 Condensed Consolidated Statements of Cash Flows 7 Notes to Unaudited Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 34 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 44 Item 4.

Controls and Procedures

Controls and Procedures 44 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 46 Item 1A.

Risk Factors

Risk Factors 46 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 46 Item 3. Defaults Upon Senior Securities 46 Item 4. Mine Safety Disclosures 46 Item 5. Other Information 46 Item 6. Exhibits 46

Signatures

Signatures 47 FORWARD-LOOKING This quarterly report on Form 10-Q (Quarterly Report), contains forward-looking statements that involve substantial risks and uncertainties. The forward-looking statements are contained principally in the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations." All statements, other than statements of historical facts, contained in this Quarterly Report, including statements regarding our strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. Words such as, but not limited to, "anticipate," "aim," "believe," "contemplate," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These

forward-looking statements include, among other things, statements about

forward-looking statements include, among other things, statements about: the consummation of the transactions contemplated by the Merger Agreement and documents related thereto; our ability to continue as a going concern; the Notice of Default and cancellation of Forbearance Agreement received by Future Pak, LLC and any potential legal action(s) against the Company, including that its assets that could be taken and potential negative outcome(s) thereof; our ability to successfully commercialize SOLOSEC (secnidazole) 2g oral granules (SOLOSEC); our ability to remediate the material weaknesses in our internal controls and procedures identified by management; our ability to obtain necessary approvals of any corporate action(s) needing stockholder, FINRA, or other approvals; our ability to file Annual and Quarterly Reports on a timely basis; our ability to raise additional capital to fund our operations if and as needed; our ability to achieve and sustain profitability; our estimates regarding our future performance including, without limitation, any estimates of potential future revenues; estimates regarding market size; our estimates regarding expenses, revenues, financial performance, and capital requirements, including the length of time our capital resources will sustain our operations; our ability to comply with the provisions and requirements of our debt arrangements, to avoid future defaults pursuant to our debt arrangements, and to pay amounts owed, including any amounts that may be accelerated, pursuant to our debt arrangements; estimates regarding health care providers' (HCPs') recommendations of PHEXXI (lactic acid, citric acid, and potassium bitartrate) vaginal gel (PHEXXI) to patients; estimates regarding HCPs' recommendations of SOLOSEC to patients suffering from the sexual health infections for which it is indicated; the rate and degree of market acceptance of our products; our ability to successfully commercialize and

View Full Filing

View this 10-Q filing on SEC EDGAR